November 23, 2016 - By Marguerite Chambers
Phillip Frost, CEO & Chairman of Opko Health Inc is the insider, our editorial team want to report about today. Mr. Phillip submitted an electronic document with the D.C. based-SEC disclosing a trade for 5,400 shares of the Pinksheet-listed company, the one he is an insider in. At the time of the legal trading transaction, the average market stock price of Opko Health Inc was $10.3, making the insider investment worth $55,523 U.S. Dollars . Phillip is trying to increase his company’s share, same as he did in the last 30 days. He acquired another 117,400 shares worth $1.11 million USD. Due to the significance of this acquisition, it will not remain unseen. Phillip Frost owns 33.67% of the -company’s market cap with a total of 183.52 million shares.
Insitutional Activity: The institutional sentiment increased to 1.8 in 2016 Q2. Its up 0.80, from 1 in 2016Q1. The ratio improved, as 33 funds sold all Opko Health Inc. shares owned while 63 reduced positions. 22 funds bought stakes while 74 increased positions. They now own 102.34 million shares or 2.14% more from 100.19 million shares in 2016Q1.
Fisher Asset Mngmt Limited Liability Co, a Washington-based fund reported 37,826 shares. Edge Wealth Mngmt Limited Co last reported 0.01% of its portfolio in the stock. Moreover, Point72 Asia (Hong Kong) has 0.02% invested in Opko Health Inc. (NASDAQ:OPK) for 2,300 shares. Moreover, Principal Fincl Grp Inc has 0% invested in Opko Health Inc. (NASDAQ:OPK) for 64,988 shares. Mivtachim The Workers Social Insurance Fund (Under Special Management) reported 3.12 million shares or 2.4% of all its holdings. Williams Jones And Assocs Lc holds 0% or 2,500 shares in its portfolio. Moreover, Capstone Invest Advisors Limited Liability Co has 0.01% invested in Opko Health Inc. (NASDAQ:OPK) for 52,966 shares. Thompson Davis Commerce Inc reported 250 shares or 0% of all its holdings. Paradigm Asset Llc, a New York-based fund reported 26,200 shares. Smith Graham & Inv Ltd Partnership, a Texas-based fund reported 568,172 shares. D E Shaw And Inc holds 0% or 26,231 shares in its portfolio. Moreover, Architects has 0.03% invested in Opko Health Inc. (NASDAQ:OPK) for 10,950 shares. Empirical Financial Svcs Llc has 20,000 shares for 0.05% of their US portfolio. Exchange Capital, a Michigan-based fund reported 30 shares. Benjamin F Edwards has 0% invested in the company for 1,250 shares.
Insider Transactions: Since May 26, 2016, the stock had 63 buys, and 0 sales for $5.61 million net activity. 1,800 shares were bought by FROST PHILLIP MD ET AL, worth $16,884.
The stock decreased 2.30% or $0.24 during the last trading session, hitting $10.2. About 200 shares traded hands. Opko Health Inc. (NASDAQ:OPK) has declined 9.65% since April 21, 2016 and is downtrending. It has underperformed by 14.98% the S&P500.
OPKO Health, Inc. is a healthcare company. The company has a market cap of $5.67 billion. The Firm operates through two divisions: diagnostics and pharmaceutical. It currently has negative earnings. The pharmaceutical segment consists of its pharmaceutical activities in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations.
According to Zacks Investment Research, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.”
Analysts await Opko Health Inc. (NASDAQ:OPK) to report earnings on March, 6. After $-0.03 actual earnings per share reported by Opko Health Inc. for the previous quarter, Wall Street now forecasts 66.67% negative EPS growth.
More news for Opko Health Inc. (NASDAQ:OPK) were recently published by: Streetinsider.com, which released: “Form 4 Opko Health, Inc. For: Nov 22 Filed by: FROST PHILLIP MD ET AL” on November 23, 2016. Seekingalpha.com‘s article titled: “OPKO Health: Significant Growth Potential From FDA Approval” and published on November 10, 2016 is yet another important article.
OPKO Health, Inc. (OPKO), incorporated on November 18, 1991, is a healthcare company. The Firm operates through two divisions: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical activities in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The Company’s pharmaceutical business features Rayaldee, a treatment for secondary hyperparathyroidism (SHPT) in patients with stage III or IV chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy-induced nausea and vomiting. The Company’s pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico. The Firm has a development and commercial supply pharmaceutical company, as well as a global supply chain operation and holding firm in Ireland. It also owns a specialty active pharmaceutical ingredients (APIs) maker in Israel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.